Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis (Q39770818)

14 September 2017

title

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis (English)

1 reference

14 September 2017

1 reference

Nicholas Mansfield

1

1 reference

14 September 2017

Sally Hamour

2

1 reference

14 September 2017

Anne-Marie Habib

3

1 reference

14 September 2017

Ruth Tarzi

4

1 reference

14 September 2017

Jeremy Levy

5

1 reference

14 September 2017

Megan Griffith

6

1 reference

14 September 2017

Tom Cairns

7

1 reference

14 September 2017

H Terence Cook

8

1 reference

14 September 2017

Charles D Pusey

9

1 reference

14 September 2017

Alan D Salama

10

1 reference

14 September 2017

language of work or name

English

0 references

publication date

17 March 2011

1 reference

Nephrology Dialysis Transplantation

14 September 2017

published in

1 reference

14 September 2017

volume

26

1 reference

14 September 2017

issue

10

1 reference

14 September 2017

page(s)

3280-3286

1 reference

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR127

21 January 2018

Identifiers

DOI

10.1093/NDT/GFR127

1 reference

14 September 2017

1 reference